Prolyl Hydroxylase Inhibitors Protect from the Bone Loss in Ovariectomy Rats by Increasing Bone Vascularity
- 459 Downloads
The hypoxia-inducible factor-1α (HIF-1α)/vascular endothelial growth factor (VEGF) pathway is involved in skeletal development, bone repair, and postmenopausal osteoporosis. Inhibitors of prolyl hydroxylases (PHD) enhance vascularity, increase callus formation in a stabilized fracture model, and activate the HIF-1α/VEGF pathway. This study examined the effects of estrogen on the HIF-1α/VEGF pathway in osteoblasts and whether PHD inhibitors can protect from bone loss in postmenopausal osteoporosis. Osteoblasts were treated with estrogen, and expressions of HIF-1α and VEGF were measured at mRNA (qPCR) and protein (Western blot) levels. Further, osteoblasts were treated with inhibitors of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathway, and levels of VEGF mRNA and protein expression were detected. In addition, ovariectomized rats were treated with PHD inhibitors, and bone microarchitecture and bone mechanical strength were assessed using micro-CT and biomechanical analyses (lower ultimate stress, modulus, and stiffness). Blood vessel formation was measured with India Ink Perfusion and immunohistochemistry. Estrogen, in a dose- and time-dependent manner, induced VEGF expression at both mRNA and protein levels and enhanced HIF-1α protein stability. Further, the estrogen-induced VEGF expression in osteoblasts involved the PI3K/Akt pathway. PHD inhibitors increased bone mineral density, bone microarchitecture and bone mechanical strength, and promoted blood vessel formation in ovariectomized rats. In conclusion, estrogen and PHD inhibitors activate the HIF-1α/VEGF pathway in osteoblasts. PHD inhibitors can be utilized to protect bone loss in postmenopausal osteoporosis by improving bone vascularity and angiogenesis in bone marrow.
KeywordsHypoxia-inducible factor Estrogen Ovariectomy Prolyl hydroxylase inhibitor Osteoblasts
This work was supported by National Natural Science Foundation of China (NSFC, No.81372015), Shanghai Natural Science Foundation (No. 11ZR1434100) and Shanghai Municipal Health Bureau Project (No. 2013214).
Conflict of interest
The authors have no conflict of interests to declare.
- 15.Chau, N. M., Rogers, P., Aherne, W., Carroll, V., Collins, I., McDonald, E., et al. (2005). Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1alpha induction in response to hypoxic stress and growth factors. Cancer Research, 65, 4918–4928.PubMedCrossRefGoogle Scholar
- 20.Yen, M. L., Su, J. L., Chien, C. L., Tseng, K. W., Yang, C. Y., Chen, W. F., et al. (2005). Diosgenin induces hypoxia-inducible factor-1 activation and angiogenesis through estrogen receptor-related phosphatidylinositol 3-kinase/Akt and p38 mitogen-activated protein kinase pathways in osteoblasts. Molecular Pharmacology, 68, 1061–1073.PubMedCrossRefGoogle Scholar
- 22.Parfitt, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. A., Malluche, H., Meunier, P. J., et al. (1987). Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. Journal of Bone and Mineral Research, 2, 595–610.PubMedCrossRefGoogle Scholar
- 29.Kang, D. H., Yu, E. S., Yoon, K. I., & Johnson, R. (2004). The impact of gender on progression of renal disease: Potential role of estrogen-mediated vascular endothelial growth factor regulation and vascular protection. American Journal of Pathology, 164, 679–688.PubMedCentralPubMedCrossRefGoogle Scholar
- 30.Sugino, N., Kashida, S., Takiguchi, S., Karube, A., & Kato, H. (2000). Expression of vascular endothelial growth factor and its receptors in the human corpus luteum during the menstrual cycle and in early pregnancy. Journal of Clinical Endocrinology and Metabolism, 85, 3919–3924.PubMedGoogle Scholar
- 31.Kazi, A. A., Jones, J. M., & Koos, R. D. (2005). Chromatin immunoprecipitation analysis of gene expression in the rat uterus in vivo: Estrogen-induced recruitment of both estrogen receptor alpha and hypoxia-inducible factor 1 to the vascular endothelial growth factor promoter. Molecular Endocrinology, 19, 2006–2019.PubMedCrossRefGoogle Scholar
- 33.Pufe, T., Claasen, H., Scholz-Ahrens, K. E., Varoga, D., Drescher, W., Franke, A. T., et al. (2007). Influence of estradiol on vascular endothelial growth factor expression in bone: A study in Göttingen miniature pigs and human osteoblasts. Calcified Tissue International, 2007, 184–191.CrossRefGoogle Scholar
- 35.Sun, M., Paciga, J. E., Feldman, R. I., Yuan, Z., Coppola, D., Lu, Y. Y., et al. (2001). Phosphatidylinositol-3-OH kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Research, 61, 5985–5991.PubMedGoogle Scholar